

Surrey and North West Sussex Area Prescribing Committee (APC)

Policy Statement	Celecoxib for the treatment of pain and inflammation
Policy No:	APC 426-2019 (replaces PCN 272-2017)
Date of Issue	July 2019
Review Date:	July 2022 (Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)
Recommendations: The Surrey & North West Sussex Area Prescribing Committee recommends celecoxib as a treatment option for the treatment of pain and inflammation in line with the product licence*. Celecoxib will be considered as GREEN on the traffic light system and is the preferred COX II inhibitor for use where a COX II inhibitor is indicated. Licenced for: Osteoarthritis, Rheumatoid Arthritis & Ankylosing Spondylitis	
Key Considerations <ul style="list-style-type: none">• Osteoarthritis: care and management Clinical guideline Published: 12 February 2014. NICE. Available at: https://www.nice.org.uk/guidance/cg177• CKS Rheumatoid arthritis. Scenario: Suspected rheumatoid arthritis. Available at: https://cks.nice.org.uk/rheumatoid-arthritis#!scenario• CKS Ankylosing spondylitis. Scenario: Suspected ankylosing spondylitis. Available at: https://cks.nice.org.uk/ankylosing-spondylitis#!scenario	
Date taken to Surrey and North West Sussex Area Prescribing Committee	3 rd July 2019
Agreed by APC members	22nd July 2019